Jade Biosciences (JBIO) closed at $15.60 on November 9, 2026, up 3.5% from the previous close, on volume of 700,501 shares (30-day average 859,084).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Jade Biosciences to Participate in Upcoming Conferences
Globe Newswire (Tue, 3-Nov 7:00 AM ET)
Globe Newswire (Wed, 21-Oct 7:00 AM ET)
Globe Newswire (Wed, 30-Sep 7:00 AM ET)
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Globe Newswire (Mon, 10-Aug 7:00 AM ET)
Market Chameleon (Thu, 4-Jun 4:39 AM ET)
Market Chameleon (Wed, 22-Apr 7:54 AM ET)
JADE201 Targets Extended Durability and Convenient Dosing in Autoimmune Therapies
Market Chameleon (Tue, 7-Oct 3:38 AM ET)
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Jade Biosciences trades on the NASDAQ stock market under the symbol JBIO.
As of November 9, 2026, JBIO stock price climbed to $15.60 with 700,501 million shares trading.
JBIO has a beta of 1.67, meaning it tends to be more sensitive to market movements. JBIO has a correlation of 0.08 to the broad based SPY ETF.
JBIO has a market cap of $992.12 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that JBIO belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
JBIO has outperformed the market in the last year with a price return of +74.3% while the SPY ETF gained +13.4%. However, in the short term, JBIO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -29.9% vs -1.8% return in SPY. But in the last 2 weeks, JBIO shares have fared better than the market returning +6.9% compared to SPY -1.0%.
JBIO support price is $14.48 and resistance is $15.67 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that JBIO shares will trade within this expected range on the day.
